课题基金 / 基金详情

PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT

PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT
3 期 AML：柔红霉素剂量加强
批准号：
7625776
负责人：
Witold B. Rybka
金额：
$3.01万
依托单位：
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-04-01 至 2008-03-31
来源：
https://reporter.nih.gov/project-details/7625776
关键词：
AutologousComputer Retrieval of Information on Scientific Projects DatabaseDaunorubicinDisease-Free SurvivalDoseFundingGemtuzumab OzogamicinGrantInstitutionPeripheral Blood Stem CellPhaseProtocols documentationResearchResearch PersonnelResourcesSourceStem cell transplantTransplantationUnited States National Institutes of Health

项目摘要

项目成果

Witold B. Rybka的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to compare disease-free survival (DFS) between two consolidation regimes: Gemtuzumab-ozogamicin followed by autologous peripheral blood stem cell (PBSC) transplant or directly to autologous transplant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET
CLINICAL TRIAL: A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION
CLINICAL TRIAL: PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL